RT Journal Article
SR Electronic
T1 Three components of glucose dynamics – value, variability, and autocorrelation – are independently associated with coronary plaque vulnerability
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.21.23298816
DO 10.1101/2023.11.21.23298816
A1 Sugimoto, Hikaru
A1 Hironaka, Ken-ichi
A1 Yamada, Tomoko
A1 Otowa-Suematsu, Natsu
A1 Hirota, Yushi
A1 Otake, Hiromasa
A1 Hirata, Ken-Ichi
A1 Sakaguchi, Kazuhiko
A1 Ogawa, Wataru
A1 Kuroda, Shinya
YR 2024
UL http://medrxiv.org/content/early/2024/09/02/2023.11.21.23298816.abstract
AB Impaired glucose homeostasis leads to numerous complications, with coronary artery disease (CAD) being a major contributor to healthcare costs worldwide. Given the limited efficacy of current CAD screening methods, we investigated the association between glucose dynamics and a predictor of coronary events measured by virtual histology-intravascular ultrasound (%NC), with the aim of predicting CAD using easy-to-measure indices. We found that continuous glucose monitoring (CGM)-derived indices, particularly average daily risk ratio (ADRR) and AC_Var, exhibited stronger predictive capabilities for %NC compared to commonly used indices such as fasting blood glucose (FBG), hemoglobin A1C (HbA1c), and plasma glucose level at 120 min during oral glucose tolerance tests (PG120). Factor analysis identified three distinct components underlying glucose dynamics – value, variability, and autocorrelation – each independently associated with %NC. ADRR was influenced by the first two components and AC_Var by the third. FBG, HbA1c, and PG120 were influenced only by the value component, making them insufficient for %NC prediction. Our results were validated using data sets from Japan (n=64), America (n=53), and China (n=100). CGM-derived indices reflecting the three components of glucose dynamics can serve as more effective screening tools for CAD risk assessment, complementing or possibly replacing traditional diabetes diagnostic methods.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (JP21H04759), CREST, the Japan Science and Technology Agency (JST) (JPMJCR2123), The Uehara Memorial Foundation, and The Takeda Science Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The retrospective observational study was approved by the ethics committee of Kobe University Graduate School of Medicine (UMIN000018326; Kobe, Japan).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe CGM data that support the findings of this study are available from the GitHub repository (https://github.com/HikaruSugimoto/CGM_regression_app).